MetaCap

Kyverna Therapeutics Insider Trades

NASDAQ: KYTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

6.39+0.21 (+3.40%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Last 12 months

Purchases
2 · $2.00M
Sales
1 · $292.78K
Shares bought / sold
266.67K / 24.00K
Net activity
Net buying $1.7 million

Kyverna Therapeutics insider activity

Over the last 12 months, Kyverna Therapeutics insiders reported 16 transactions on SEC Form 4: 2 open-market purchases and 1 sale. Insiders bought $2.0 million and sold $292,776 worth of stock, for net insider buying of $1.7 million. The largest seller was Walker Karen Marie, with $292,776 in reported sales.

The most recent filing shows SEIDENBERG BETH C (Director) reporting a transaction in 5,093 shares on May 27, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put KYTX's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

KYTX insider transactions

Kyverna Therapeutics insider transactions
DateInsiderTypeSharesValueFiling
May 27, 2026Cohen Fred EDirectorAward5,093—Form 4
May 27, 2026CLARK IAN TDirectorAward5,093—Form 4
May 27, 2026Aktar MertDirectorAward5,093—Form 4
May 27, 2026Shaw ChristiExecutive ChairpersonTax withholding4,194$36.03KForm 4
May 27, 2026SEIDENBERG BETH CDirectorAward5,093—Form 4
Mar 13, 2026GEHCHAN NAJISee RemarksAward18,000—Form 4
Mar 13, 2026Biddle Warner WestonChief Executive OfficerAward58,000—Form 4
Mar 13, 2026GRASSO MARCChief Financial OfficerAward10,000—Form 4
Feb 24, 2026Emany Sravan KumarDirectorAward11,006—Form 4
Feb 24, 2026Miller Andrew CraigDirectorAward11,006—Form 4
Jan 12, 2026Shaw ChristiExecutive ChairpersonAward24,301—Form 4
Jan 12, 2026Shaw ChristiExecutive ChairpersonAward30,000—Form 4
Dec 18, 2025Westlake BioPartners Opportunity Fund I, L.P. & Westlake BioPartners Opportunity GP I, LLC & Westlake BioPartners Fund I, L.P. & Westlake BioPartners GP I, LLC10% OwnerBuy133,333$1000.00KForm 4
Dec 18, 2025SEIDENBERG BETH CDirectorBuy133,333$1000.00KForm 4
Dec 15, 2025Walker Karen MarieChief Technology OfficerSale23,998$292.78KForm 4
Dec 15, 2025Walker Karen MarieChief Technology OfficerOption exercise23,998$115.91KForm 4
May 29, 2025Cohen Fred EDirectorAward16,634—Form 4
May 29, 2025Aktar MertDirectorAward16,634—Form 4
May 29, 2025SPIEGELMAN DANIEL KDirectorAward16,634—Form 4
May 29, 2025SEIDENBERG BETH CDirectorAward16,634—Form 4
May 29, 2025CLARK IAN TDirectorAward16,634—Form 4
May 29, 2025Shaw ChristiDirectorAward16,634—Form 4
Apr 11, 2025Walker Karen MarieChief Technology OfficerAward13,000—Form 4
Apr 11, 2025Jones Ryan AlexanderChief Financial OfficerAward12,000—Form 4
Jun 6, 2024Walker Karen MarieChief Technology OfficerOption exercise9,636$42.59KForm 4
May 28, 2024Jones Ryan AlexanderChief Financial OfficerOption exercise7,146$5.22KForm 4
May 28, 2024Jones Ryan AlexanderChief Financial OfficerOption exercise10,870$7.94KForm 4
Feb 12, 2024GILEAD SCIENCES, INC.10% OwnerBuy910,000$20.02MForm 4
Feb 12, 2024GILEAD SCIENCES, INC.10% OwnerConversion3,216,119—Form 4
Feb 12, 2024SEIDENBERG BETH CDirectorConversion735,984—Form 4
Feb 12, 2024SEIDENBERG BETH CDirectorConversion3,787,940—Form 4
Feb 12, 2024Cohen Fred EDirectorConversion4,523,924—Form 4
Feb 12, 2024Vida Ventures, LLC & Vida Ventures GP III, L.L.C. & Vida Ventures III, L.P. & Vida Ventures III-A, L.P.10% OwnerBuy583$12.83KForm 4
Feb 12, 2024Vida Ventures, LLC & Vida Ventures GP III, L.L.C. & Vida Ventures III, L.P. & Vida Ventures III-A, L.P.10% OwnerBuy252,553$5.56MForm 4
Feb 12, 2024Vida Ventures, LLC & Vida Ventures GP III, L.L.C. & Vida Ventures III, L.P. & Vida Ventures III-A, L.P.10% OwnerConversion4,523,924—Form 4
Feb 12, 2024Bain Capital Life Sciences Investors, LLC & Bain Capital Life Sciences III General Partner, LLC & Bain Capital Life Sciences Fund III, L.P. & Bain Capital Life Sciences Opportunities III GP, LLC & Bain Capital Life Sciences Opportunities III, LP10% OwnerBuy450,000$9.90MForm 4
Feb 12, 2024Bain Capital Life Sciences Investors, LLC & Bain Capital Life Sciences III General Partner, LLC & Bain Capital Life Sciences Fund III, L.P. & Bain Capital Life Sciences Opportunities III GP, LLC & Bain Capital Life Sciences Opportunities III, LP10% OwnerConversion2,713,868—Form 4
Feb 12, 2024Westlake BioPartners Fund I, L.P. & Westlake BioPartners GP I, LLC & Westlake BioPartners Opportunity Fund I, L.P. & Westlake BioPartners Opportunity GP I, LLC & Harper Sean E10% OwnerConversion735,984—Form 4
Feb 12, 2024Westlake BioPartners Fund I, L.P. & Westlake BioPartners GP I, LLC & Westlake BioPartners Opportunity Fund I, L.P. & Westlake BioPartners Opportunity GP I, LLC & Harper Sean E10% OwnerConversion3,787,940—Form 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related